Cancer growth may be blocked by two proteins that bind together to stop cell signaling, research at the Walter and Eliza Hall Institute claims.
The atomic-level structure of SOCS1 binding to its partner protein JAK could guide the development of drugs that alter disease-causing cell signaling pathways, and may have applications for treating some blood cancers, including leukemia.
At a Glance
- The SOCS1 protein binds to JAK proteins to 'switch off' cell signaling, which dampens processes including immune responses and cancer growth.
- Our researchers have used structural biology to visualize how SOCS1 binds to JAK proteins in never-before seen detail.
- The detailed structure may guide the development of new drugs that modify JAK activity, amplifying or dampening cell responses, with potential applications in cancer therapies.
Dr Liau said the structure of the protein pair revealed for the first time how SOCS1 binds to JAK proteins to disable signaling.
"With this image, we were able to explain for the first time why JAK proteins cannot signal when bound to SOCS1. This information could help to underpin the development of new medicine targeting this important cell signaling pathway."
A Blueprint for New Medicines
Dr Kershaw said both SOCS1 and JAK proteins had been implicated in driving diseases including cancer and inflammatory conditions.
"In particular, overactive JAK signaling is linked to the development of cancer-like conditions called myeloproliferative neoplasms (MPNs) - which include polycythemia vera, essential thrombocythemia and primary myelofibrosis - as well as certain acute childhood leukemia.
"Medicines that inhibit JAK signaling are in use for treating MPNs, but they are only able to manage the disease, not cure it. New medicines for these conditions are needed, and we envisage that a drug designed to mimic the SOCS1 protein to switch off JAK proteins might be a more effective treatment," Dr Kershaw said.
As well as guiding the development of drugs mimicking SOCS1, the team's research may also underpin the development of a second new class of drugs that inhibit SOCS1, Associate Professor Jeff Babon said. "SOCS1 binding JAK proteins normally applies a 'brake' to immune responses - which in a healthy person is a good thing," he said.
"However, in certain conditions, releasing this brake could be the key to enhanced immune responses. This approach to boosting the immune response could be the key to improving immunotherapies for treating cancer. If we could design a drug that inhibits SOCS1, this might boost anti-cancer immune responses, potentially improving anti-cancer immunotherapies."
The study is published in the journal Nature Communications.